论文部分内容阅读
ＨｙｐｅｒＧＡＭ＋ＣＦ进入Ⅱ期临床试验美国尤尼瓦克生物技术公司（ＵｎｉｖａｘＢｉｏ－ｌｏｇｉｃｓ）的ＨｙＰｅｒＧＡＭ＋ＣＦ已进入Ⅱ期临床试验。其多克隆抗体用于抑制和治疗囊肿病人的复发性急性肺炎。该药的作用靶是绿脓杆菌，这是导致ＣＦ患者得病和致死的主要...
HyperGAM + CF enters Phase II clinical trial HyPerGAM + CF from Univax Bio-logics has entered Phase II clinical trial. Its polyclonal antibody is used to suppress and treat recurrent acute pneumonia in cystic patients. The drug’s target is Pseudomonas aeruginosa, which is the leading cause of CF patients and death of the main ...